MetaCap

Elicio Therapeutics Inc. (ELTX)

NASDAQ: ELTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.45-0.05 (-3.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ELTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$41.05M
EPS (TTM)
-$1.81
52-week range
1.25 – 16.00
Day range
1.44 – 1.59
Volume / Avg
231.62K / 324.71K
Beta
—

52-week range

$1.25$16.00

ELTX stock today

Shares of Elicio Therapeutics (ELTX) finished lower on Nov 20 at $1.45, a drop of 3.33% or $0.05 per share, versus the S&P 500's 3.70% decline. Shares are 90.9% below their 52-week high of $16.00, set on Jun 10, 2026 and 16.0% above the 52-week low of $1.25, near the bottom of the past year's range. ELTX is down 81.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%.

Elicio Therapeutics has posted a net loss over the last twelve months (EPS of -$1.81), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Elicio Therapeutics

Company profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert T. Connelly
Headquarters
Boston, MA
Employees
33
IPO year
2021
Website
elicio.com

Financial highlights

Full financials

Elicio Therapeutics reported a net loss of $39.6 million, compared with a loss of $51.9 million a year earlier. Diluted earnings per share came in at -$2.58.

Elicio Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$2.30M$28.31M
Growth———-91.87%+883.06%
Net income$-39.57M$-51.90M$-35.20M$-28.21M$-54.57M
EPS (diluted)$-2.58$-4.25$-6.96$-89.27$-1.93

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$13.67+842.76%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $23.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.30 vs $-0.42
Surprise
+28.57%

ELTX news

All ELTX news

Elicio Therapeutics peers

Health Care sector
ELTX peer companies
CompanyPrice% ChgMarket capCompare
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs ELTX
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs ELTX
BMEABiomea Fusion Inc.0.5744-2.38%$41.75Mvs ELTX
OSTXOS Therapies Incorporated0.803-2.12%$42.00Mvs ELTX
INCRIntercure Ltd.3.24-7.69%$42.03Mvs ELTX
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs ELTX
DWTXDogwood Therapeutics Inc.1.04-2.36%$39.57Mvs ELTX
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs ELTX

Indexes, lists and sector

Elicio Therapeutics stock FAQ

What is Elicio Therapeutics's stock price today?

ELTX last traded at $1.45 as of Nov 20, 4:00 PM EST, down 3.33% on the day. Prices are delayed at least 15 minutes.

Does Elicio Therapeutics pay a dividend?

No. Elicio Therapeutics does not currently pay a regular cash dividend.

Who is Elicio Therapeutics's CEO?

Mr. Robert T. Connelly is the chief executive officer of Elicio Therapeutics Inc., which has about 33 employees.

Has ELTX ever split its stock?

Yes. The most recent ELTX stock split was a 1-for-10 split on Jun 2, 2023.

What is the ELTX 52-week high?

The 52-week high for ELTX is $16.00 and the 52-week low is $1.25. The stock is currently 90.9% below its high.

Compare ELTX